

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

VOLUNTARY ANNOUNCEMENT

SUCCESSFULLY ADMINISTERS FIRST DOSE IN HUMAN FOR NOVEL RADIOACTIVE DRUG CONJUGATE 3D1015

The Board of Directors is pleased to announce that the Company's first radioactive drug conjugate (RDC)¹⁷⁷Lu-PSMA-3D1015 ("3D1015"), which was discovered in house, has dosed the first patient successfully. The study aims to evaluate the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

The study specifically targets patients with PSMA-positive mCRPC – a population with significant unmet clinical needs. The trial will systematically evaluate the core clinical value of 3D1015, focusing on assessing the drug's safety and radiation dosimetry, while extensively collecting pharmacokinetic data and dose-exploration findings in humans. These results will provide critical clinical evidence for determining dosage and managing risks in subsequent registrational clinical trials.

The Company cannot guarantee the successful development and commercialization of 3D1015. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's shares.

By order of the Board

3D Medicines Inc.

Dr. Gong Zhaolong

Chairman of the Board

Hong Kong

August 28, 2025

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Jinqiao, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.